All Stories

  1. Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 Study
  2. Omission of Chest-Wall Irradiation after Mastectomy for Breast Cancer
  3. Optimising mastectomy with a focus on skin and nipple-sparing approaches: a multidisciplinary point of view
  4. Artificial intelligence in breast cancer radiotherapy: Insights from the Toolbox Consortium Delphi study
  5. Corrigendum to “Artificial intelligence in breast cancer radiotherapy: Insights from the Toolbox Consortium Delphi study” [The Breast, Volume 83 (2025) 104537]
  6. What guides regional nodal irradiation in node positive breast cancer following upfront sentinel lymph node biopsy?
  7. Lost axillary markers after neoadjuvant chemotherapy in breast cancer patients - data from the prospective international AXSANA (EUBREAST 3) cohort study (NCT04373655)
  8. BJS commission on the surgical management of the axilla in breast cancer
  9. Local management of second breast cancer event after primary breast conserving therapy: The patient’s perspective
  10. Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA cohort study
  11. Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients – Results from the prospective AXSANA registry trial
  12. Impact of axillary staging after neoadjuvant chemotherapy for breast cancer on arm morbidity: one-year results from the AXSANA cohort study
  13. Impact of prior radiotherapy and implant-based reconstruction on microvascular outcome in DIEP flap breast reconstruction
  14. Long-term oncological outcomes after nipple-sparing mastectomy and implant-based immediate breast reconstruction in a large population-based cohort
  15. Survival after breast conservation versus mastectomy in ductal carcinoma in situ of the breast: a population-based Swedish register study
  16. Abstract P2-10-25: AXSANA: Status of the international prospective multicenter cohort study evaluating different surgical methods of axillary staging in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy (NCT04373655)
  17. Abstract RF2-03: Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients – results from the prospective AXSANA registry trial (NCT04373655)
  18. Abstract P3-12-16: MELODY: A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions (EUBREAST-4 / iBRA-NET, NCT 05559411)
  19. Abstract P3-10-29: Start of SerMa – EUBREAST 5 (Seroma of the Mammary Gland) study (NCT05899387) - On the way to identify women at risk of developing seroma after mastectomy
  20. Abstract PS6-06: Upstage of N-Stage by Diagnostic Axillary Lymph Node Dissection in Patients w/ Isolated Tumor Cells or Micrometastases in Sentinel/Target Lymph Node after Neoadjuvant Chemotherapy - Results from the Prospective Multicenter AXSANA / EUB...
  21. Comparison of marking techniques for target lymph nodes in 2,596 patients with node-positive breast cancer treated with neoadjuvant chemotherapy: Results from the prospective multicenter AXSANA/EUBREAST-03/AGO-B-053 study (NCT04373655).
  22. Setting a precedent: Development of a core outcome set for locoregional treatment outcome reporting in neoadjuvant breast cancer trials.
  23. Omitting completion axillary lymph node dissection in breast cancer patients with sentinel lymph node micrometastases undergoing mastectomy: results from the prospective SENOMIC trial
  24. Treatment strategies for triple-negative primary breast cancer in older women: a systematic review
  25. Radar reflectors for marking of target lymph nodes in initially node-positive patients receiving neoadjuvant chemotherapy for breast cancer—a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial
  26. P286: Radar localization for targeted axillary dissection in breast cancer patients undergoing primary systemic treatment: a sub-analysis of the AXSANA study
  27. P464: Treatment Strategies for Triple-Negative Primary Breast Cancer in Older Women: A Systematic Review
  28. Radiation therapy volumes after primary systemic therapy in breast cancer patients: an international EUBREAST survey
  29. Prediction of High Nodal Burden in Patients With Sentinel Node–Positive Luminal ERBB2-Negative Breast Cancer
  30. Axillary clearance and chemotherapy rates in ER+HER2− breast cancer: secondary analysis of the SENOMAC trial
  31. ‘Balancing Challenges and Personal Resources’: A Qualitative Study of Women's Experiences of Arm Impairment After Axillary Surgery for Breast Cancer
  32. Idiopathic Granulomatous Mastitis as a Benign Condition Mimicking Inflammatory Breast Cancer: Current Status, Knowledge Gaps and Rationale for the GRAMAREG Study (EUBREAST-15)
  33. Exploring locoregional treatment reporting in neoadjuvant systemic breast cancer treatment studies: A systematic review
  34. Surgical complications after immediate implant-based breast reconstruction for breast cancer in women over 65 years
  35. Completion axillary lymph node dissection for the identification of pN2–3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial
  36. Timing and type of breast reconstruction in SweBRO 3: long-term outcomes
  37. Quality assessment of radiotherapy in the prospective randomized SENOMAC trial
  38. 71486 - Surgical complications after immediate implant-based breast reconstruction for breast cancer in women ≥ 65 years of age
  39. 71487 - The role of previous implant-based breast reconstruction and radiotherapy for surgical complications in DIEP breast reconstruction
  40. Abstract PO4-19-04: AXSANA – EUBREAST-3: An international prospective multicenter cohort study to evaluate different surgical methods of axillary staging in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy
  41. Abstract PO5-19-02: I-PREPARE: International Prospective REgistry on Pre-pectorAl breast Reconstruction (EUBREAST 11R-NCT 05817175)
  42. Abstract PO4-18-12: MELODY: A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions (EUBREAST-4/iBRA-NET, NCT 05559411)
  43. Abstract PO1-23-02: Magnetic seeds used for the detection of target lymph nodes after neoadjuvant therapy for early breast cancer – a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial
  44. Abstract PO1-19-06: Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: the randomized Neo-ACT trial
  45. Abstract PO3-23-03: Radar reflectors for marking of target lymph nodes in patients receiving neoadjuvant chemotherapy for breast cancer – a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial
  46. Abstract GS02-06: Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection – first results from the international randomized SENOMAC trial
  47. Abstract PO1-19-03: The T-REX trial: a randomized international non-inferiority trial on Tailored Regional EXternal beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases
  48. Which real indications remain for mastectomy?
  49. Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases
  50. Protocol for the development of a core outcome set and reporting guidelines for locoregional treatment in neoadjuvant systemic breast cancer treatment trials: the PRECEDENT project
  51. Targeted axillary dissection: worldwide variations in clinical practice
  52. National long-term patient-reported outcomes following mastectomy with or without breast reconstruction: The Swedish Breast Reconstruction Outcome Study Part 2 (SweBRO 2)
  53. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
  54. Applicability of magnetic seeds for target lymph node biopsy after neoadjuvant chemotherapy in initially node-positive breast cancer patients: data from the AXSANA study
  55. Protocol for the T-REX-trial: tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases – an open, multicentre, randomised non-inferiority phase 3 trial
  56. The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus
  57. Uncertainties and controversies in axillary management of patients with breast cancer
  58. MELODY (Methods for Localization of Different Types of Breast Lesions): A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions (EUBREAST-4/iBRA-NET).
  59. EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy
  60. Localization Techniques for Non-Palpable Breast Lesions: Current Status, Knowledge Gaps, and Rationale for the MELODY Study (EUBREAST-4/iBRA-NET, NCT 05559411)
  61. Axillary staging in node-positive breast cancer converting to node negativity through neoadjuvant chemotherapy: Current evidence and perspectives
  62. Locoregional Therapy: From Mastectomy to Reconstruction, Targeted Surgery, and Ultra-Hypofractionated Radiotherapy
  63. Capsular inflammation after immediate breast reconstruction – Gene expression patterns and inflammatory cell infiltration in irradiated and non-irradiated breasts
  64. Medical and surgical postoperative complications after breast conservation versus mastectomy in older women with breast cancer: Swedish population-based register study of 34 139 women
  65. Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: Trial protocol of the randomized Neo-ACT trial
  66. Current trends in diagnostic and therapeutic management of the axilla in breast cancer patients receiving neoadjuvant therapy: results of the German-wide NOGGO MONITOR 24 survey
  67. Effectiveness of Single vs Multiple Doses of Prophylactic Intravenous Antibiotics in Implant-Based Breast Reconstruction
  68. Long-term outcomes of implant-based immediate breast reconstruction with and without radiotherapy: a population-based study
  69. Major surgical postoperative complications and survival in breast cancer: Swedish population-based register study in 57 152 women
  70. Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey
  71. Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy
  72. Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial
  73. AXSANA – AXillary Surgery After NeoAdjuvant Treatment: Eine prospektive, multizentrische Kohortenstudie der EUBREAST-Studiengruppe zur Bewertung verschiedener chirurgischer Verfahren des axillären Stagings bei initial nodal-positiven PatientInnen nach ...
  74. 120P AXSANA (AXillary Surgery After NeoAdjuvant Treatment) EUBREAST-3: An international prospective multicenter cohort study to evaluate different surgical methods of axillary staging in clinically node-positive breast cancer patients treated with neoa...
  75. False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy
  76. Abstract OT1-04-04: AXSANA - EUBREAST 3 (axillary surgery after neoadjuvant treatment): An international prospective multicenter cohort study of the EUBREAST study group to evaluate different surgical methods of axillary staging (sentinel lymph node bi...
  77. Abstract P1-01-16: Perspectives on axillary management after primary systemic treatment: An international EUBREAST survey
  78. Eradication of Potential In-Transit Metastasis in Breast-Conserving Surgery—Reply
  79. Effect of radiotherapy on expanders and permanent implants in immediate breast reconstruction: long-term surgical and patient-reported outcomes in a large multicentre cohort
  80. ASO Visual Abstract: Retrospective Multicenter Analysis Comparing Conventional with Oncoplastic Breast-Conserving Surgery: Oncological and Surgical Outcomes in Women with High-Risk Breast Cancer from the OPBC-01/iTOP2 Study
  81. Retrospective, Multicenter Analysis Comparing Conventional with Oncoplastic Breast Conserving Surgery: Oncological and Surgical Outcomes in Women with High-Risk Breast Cancer from the OPBC-01/iTOP2 Study
  82. Survival in breast cancer patients with a delayed DIEP flap breast reconstruction after adjustment for socioeconomic status and comorbidity
  83. Targeted Removal of Axillary Lymph Nodes After Carbon Marking in Patients with Breast Cancer Treated with Primary Chemotherapy
  84. Prepectoral versus subpectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing ...
  85. Survival After Breast Conservation vs Mastectomy Adjusted for Comorbidity and Socioeconomic Status
  86. Axillary Pathologic Complete Response After Neoadjuvant Systemic Therapy by Breast Cancer Subtype in Patients With Initially Clinically Node-Positive Disease
  87. Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial
  88. Long-term prognosis in breast cancer is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status
  89. Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study
  90. Carbon tattooing for targeted lymph node biopsy after primary systemic therapy in breast cancer: prospective multicentre TATTOO trial
  91. Recurrence and survival after standard versus oncoplastic breast-conserving surgery for breast cancer
  92. Breast reconstruction patterns from a Swedish nation-wide survey
  93. AXSANA (AXillary Surgery After NeoAdjuvant Treatment): A European prospective multicenter cohort study to evaluate different surgical methods of axillary staging (sentinel lymph node biopsy, targeted axillary dissection, axillary dissection) in clinica...
  94. Target Lymph Node Biopsy (TLNB) nach Kohlenstoffmarkierung bei Mammakarzinom-Patientinnen im Rahmen der primären Systemtherapie – Ergebnisse der TATTOO-Studie
  95. Risk factors for implant failure following revision surgery in breast cancer patients with a previous immediate implant-based breast reconstruction
  96. Knowledge gaps in oncoplastic breast surgery
  97. AXSANA (AXillary Surgery After NeoAdjuvant Treatment): A European prospective multicenter cohort study to evaluate different surgical methods of axillary staging (sentinel lymph node biopsy, targeted axillary dissection, axillary dissection) in clinica...
  98. TLNB (Target-Lymph-Node-Biopsy) nach Kohlenstoffmarkierung bei Mammakarzinom-Patientinnen nach primärer Systemtherapie Ergebnisse der TATTOO-Studie
  99. Abstract OT3-01-01: Feasibility of carbon tattooing for targeted lymph node biopsy in breast cancer patients treated by primary systemic therapy (TATTOO trial)
  100. CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment
  101. Breast and axillary surgery in malignant breast disease: a review focused on literature of 2018 and 2019
  102. Influence of socioeconomic status on immediate breast reconstruction rate, patient information and involvement in surgical decision-making
  103. The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer
  104. Immediate Breast Reconstruction
  105. Socioeconomic status differs between breast cancer patients treated with mastectomy and breast conservation, and affects patient-reported preoperative information
  106. Do clinical trials truly mirror their target population? An external validity analysis of national register versus trial data from the Swedish prospective SENOMIC trial on sentinel node micrometastases in breast cancer
  107. Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant
  108. A gap analysis of opportunities and priorities for breast surgical research
  109. Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy
  110. Breast-conserving surgery followed by whole-breast irradiation offers survival benefits over mastectomy without irradiation
  111. Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes
  112. Risk of recurrence and death in patients with breast cancer after delayed deep inferior epigastric perforator flap reconstruction
  113. Current Status and Future Perspectives of Axillary Management in the Neoadjuvant Setting
  114. What Is the Best Management of cN0pN1(sn) Breast Cancer Patients
  115. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial
  116. Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer
  117. Swedish prospective multicenter trial on the accuracy and clinical relevance of sentinel lymph node biopsy before neoadjuvant systemic therapy in breast cancer
  118. Ten-year report on axillary recurrence after negative sentinel node biopsy for breast cancer from the Swedish Multicentre Cohort Study
  119. Impact of previous surgery on sentinel lymph node mapping: Hybrid SPECT/CT before and after a unilateral diagnostic breast excision
  120. National study of the impact of patient information and involvement in decision-making on immediate breast reconstruction rates
  121. Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer
  122. The oncological safety of nipple-sparing mastectomy – A Swedish matched cohort study
  123. Oestrogen receptors β1 and βcx have divergent roles in breast cancer survival and lymph node metastasis
  124. Incidence of and risk factors for sentinel lymph node metastasis in patients with a postoperative diagnosis of ductal carcinomain situ
  125. Radiotherapy in implant-based immediate breast reconstruction: risk factors, surgical outcomes, and patient-reported outcome measures in a large Swedish multicenter cohort
  126. Authors' reply: Causes of false-negative sentinel node biopsy in patients with breast cancer (Br J Surg2013; 100: 775-783)
  127. High Prevalence of Human Cytomegalovirus Proteins and Nucleic Acids in Primary Breast Cancer and Metastatic Sentinel Lymph Nodes
  128. Causes of false-negative sentinel node biopsy in patients with breast cancer
  129. Tumor-dependent increase of serum amino acid levels in breast cancer patients has diagnostic potential and correlates with molecular tumor subtypes
  130. Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients
  131. Tumor-induced changes in the phenotype of blood-derived and tumor-associated T cells of early stage breast cancer patients
  132. Prediction of Non-Sentinel Lymph Node Status in Breast Cancer Patients with Sentinel Lymph Node Metastases: Evaluation of the Tenon Score
  133. Axillary recurrence rate 5 years after negative sentinel node biopsy for breast cancer
  134. Tumor-dependent down-regulation of the ζ-chain in T-cells is detectable in early breast cancer and correlates with immune cell function
  135. Breast Cancer Survival in Relation to the Metastatic Tumor Burden in Axillary Lymph Nodes
  136. Axillary Recurrence Rate After Negative Sentinel Node Biopsy in Breast Cancer
  137. Sentinel node biopsy for breast cancer larger than 3 cm in diameter